Literature DB >> 9811721

Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.

C Spenlehauer1, S Saragosti, H J Fleury, A Kirn, A M Aubertin, C Moog.   

Abstract

Previous studies characterized the third variable (V3) loop of the envelope gp120 as the principal neutralizing determinant for laboratory T-cell-line-adapted (TCLA) strains of human immunodeficiency virus type 1 (HIV-1). However, primary viruses isolated from infected individuals are more refractory to neutralization than TCLA strains, suggesting that qualitatively different neutralizing antibodies may be involved. In this study, we investigated whether the V3 loop constitutes a linear target epitope for antibodies neutralizing primary isolates. By using peptides representative of the V3 regions of various primary isolates, an early, relatively specific and persistent antibody response was detected in sera from HIV-infected patients. To assess the relationship between these antibodies and neutralization, the same peptides were used in competition and depletion experiments. Addition of homologous V3 peptides led to a competitive inhibition in the neutralization of the TCLA strain HIVMN/MT-4 but had no effect on the neutralization of the autologous primary isolate. Similarly, the removal of antibodies that bind to linear V3 epitopes resulted in a loss of HIVMN/MT-4 neutralization, whereas no decrease in the autologous neutralization was measured. The different roles of V3-specific antibodies according to the virus considered were thereby brought to light. This confirmed the involvement of V3 antibodies in the neutralization of a TCLA strain but emphasized a more pronounced contribution of either conformational epitopes or epitopes outside the V3 loop as targets for antibodies neutralizing primary HIV-1 isolates. This result underlines the need to focus on new vaccinal immunogens with epitopes able to induce broadly reactive and efficient antibodies that neutralize a wide range of primary HIV-1 isolates.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811721      PMCID: PMC110497          DOI: 10.1128/JVI.72.12.9855-9864.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

1.  V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity.

Authors:  L A Ivanoff; J W Dubay; J F Morris; S J Roberts; L Gutshall; E J Sternberg; E Hunter; T J Matthews; S R Petteway
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

2.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Authors:  A Trkola; T Dragic; J Arthos; J M Binley; W C Olson; G P Allaway; C Cheng-Mayer; J Robinson; P J Maddon; J P Moore
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

3.  Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope.

Authors:  R R Garrity; G Rimmelzwaan; A Minassian; W P Tsai; G Lin; J J de Jong; J Goudsmit; P L Nara
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

4.  Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development.

Authors:  T J Matthews
Journal:  AIDS Res Hum Retroviruses       Date:  1994-06       Impact factor: 2.205

5.  Inhibition of HIV-1 infection by the beta-chemokine MDC.

Authors:  R Pal; A Garzino-Demo; P D Markham; J Burns; M Brown; R C Gallo; A L DeVico
Journal:  Science       Date:  1997-10-24       Impact factor: 47.728

6.  Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.

Authors:  A K Pilgrim; G Pantaleo; O J Cohen; L M Fink; J Y Zhou; J T Zhou; D P Bolognesi; A S Fauci; D C Montefiori
Journal:  J Infect Dis       Date:  1997-10       Impact factor: 5.226

7.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

9.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.

Authors:  C Moog; H J Fleury; I Pellegrin; A Kirn; A M Aubertin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

10.  Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.

Authors:  J P Moore; D D Ho
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

View more
  27 in total

1.  Conservation of human immunodeficiency virus type 1 gp120 inner-domain sequences in lentivirus and type A and B retrovirus envelope surface glycoproteins.

Authors:  I Hötzel; W P Cheevers
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.

Authors:  H X Liao; B Etemad-Moghadam; D C Montefiori; Y Sun; J Sodroski; R M Scearce; R W Doms; J R Thomasch; S Robinson; N L Letvin; B F Haynes
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Authors:  Chavdar Krachmarov; Abraham Pinter; William J Honnen; Miroslaw K Gorny; Phillipe N Nyambi; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation.

Authors:  Vincent Holl; Maryse Peressin; Sylvie Schmidt; Thomas Decoville; Susan Zolla-Pazner; Anne-Marie Aubertin; Christiane Moog
Journal:  Blood       Date:  2006-02-09       Impact factor: 22.113

5.  Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.

Authors:  Xueling Wu; Anna Sambor; Martha C Nason; Zhi-Yong Yang; Lan Wu; Susan Zolla-Pazner; Gary J Nabel; John R Mascola
Journal:  Virology       Date:  2008-09-18       Impact factor: 3.616

6.  Neutralization potential of the plasma of HIV-1 infected Indian patients in the context of anti-V3 antibody content and antiretroviral therapy. [corrected].

Authors:  Alok Kumar Choudhary; Raiees Andrabi; Somi Sankaran Prakash; Rajesh Kumar; Shubhasree Dutta Choudhury; Naveet Wig; Ashutosh Biswas; Anjali Hazarika; Kalpana Luthra
Journal:  J Microbiol       Date:  2012-02-27       Impact factor: 3.422

7.  Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate.

Authors:  C H Chen; L Jin; C Zhu; S Holz-Smith; T J Matthews
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

8.  Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India.

Authors:  Smita Kulkarni; Srikanth Tripathy; Raman Gangakhedkar; Sushama Jadhav; Kalpana Agnihotri; Suvarna Sane; Robert Bollinger; Ramesh Paranjape
Journal:  AIDS Res Hum Retroviruses       Date:  2008-09       Impact factor: 2.205

9.  Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.

Authors:  Renaud Burrer; Sandrine Haessig-Einius; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.

Authors:  C Spenlehauer; A Kirn; A M Aubertin; C Moog
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.